Cited by 209Adipokines, Inflammation, and Metabolic DiseasesMetabolism, Diabetes, and CancerCytokine Signaling Pathways and Interactions

Dual Role of Interleukin-6 in Regulating Insulin Sensitivity in Murine Skeletal Muscle

Open access
Nieto-Vazquez, Iria, Fernández-Veledo, Sonia, de Alvaro, Cristina, Lorenzo, Margarita·2008·Diabetes

Abstract

OBJECTIVE—Cytokines are elevated in various insulin-resistant states, including type 2 diabetes and obesity, although the contribution of interleukin-6 (IL-6) in the induction of these diseases is controversial. RESEARCH DESIGN AND METHODS—We analyzed the impact of IL-6 on insulin action in murine primary myocytes, skeletal muscle cell lines, and mice (wild type and protein-tyrosine phosphatase 1B [PTP1B] deficient). RESULTS—IL-6 per se increased glucose uptake by activating serine/threonine protein kinase 11 (LKB1)/AMP-activated protein kinase/protein kinase B substrate of 160 kDa (AS160) pathway. A dual effect on insulin action was observed when myotubes and mice were exposed to this cytokine: additive with short-term insulin (increased glucose uptake and systemic insulin sensitivity) but chronic exposure produced insulin resistance (impaired GLUT4 translocation to plasma membrane and defects in insulin signaling at the insulin receptor substrate 1 [IRS-1] level). Three mechanisms seem to operate in IL-6–induced insulin resistance: activation of c-Jun NH2-terminal kinase 1/2 (JNK1/2), accumulation of suppressor of cytokine signaling 3 (socs3) mRNA, and an increase in PTP1B activity. Accordingly, silencing JNK1/2 with either small interfering RNA or chemical inhibitors impaired phosphorylation of IRS-1 (Ser307), restored insulin signaling, and normalized insulin-induced glucose uptake in myotubes. When using a pharmacological approach, liver X receptor agonists overcome IL-6–induced insulin resistance by producing downregulation of socs3 and ptp1b gene expression. Finally, the lack of PTP1B confers protection against IL-6–induced insulin resistance in skeletal muscle in vitro and in vivo, in agreement with the protection against the IL-6 hyperglycemic effect observed on glucose and insulin tolerance tests in adult male mice. CONCLUSIONS—These findings indicate the important role of IL-6 in the pathogenesis of insulin resistance and further implicate PTP1B as a potential therapeutic target in the treatment of type 2 diabetes.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/db07-1062This paper is marked retracted.

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Chronic treatment with IL-6 induces insulin resistance via mechanisms involving protein-tyrosine phosphatase 1B, JNK activation and SOCS3-mediated inhibition of insulin signaling, while acute exposure enhances insulin-stimulated glucose uptake via the LKB1/AMPK/TBC1D4 pathway.

    “The following year, Nieto-Vazquez et al. [166] found that the differential effects of IL-6 may be due to the amount of exposure to the cytokine, whereby, chronic treatment induces insulin resistance via mechanisms involving protein-tyrosine phosphatase 1B, JNK activation and SOCS3-mediated inhibition of insulin signaling, while acute exposure enhances insulin-stimulated glucose uptake via the LKB1”

    From AMPK and Exercise: Glucose Uptake and Insulin Sensitivity (2013) · cites this paper as [166]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

2 retracted

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Nieto-Vazquez, I., Fernández-Veledo, S., de Alvaro, C., & Lorenzo, M.
Affiliations
  • 1Department of Biochemistry and Molecular Biology II, Faculty of Pharmacy, Complutense University, Madrid, Spain
  • Universidad Complutense de Madrid (ES)
Corresponding author
Lorenzo, Margarita
Venue
Diabetes
Published
2008-12-01
Volume
57
Issue
12
Pages
3211-3221
ISSN
  • 0012-1797 (ISSN-L)
  • 1939-327X
OpenAlex
W2104603426
Cited by
209
References
52
Citations by year
2026: 3 · 2024: 4 · 2023: 4 · 2022: 4 · 2021: 6 · 2020: 17 · 2019: 17 · 2018: 14 · 2017: 17 · 2016: 15 · 2015: 16 · 2014: 16 · 2013: 17 · 2012: 9
FWCI
12.21
Type
journal article
Language
en
Status
Retracted
Open access
Licence
cc-by-nc-nd
Locations
  • Diabetes (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • Comunidad de Madrid
  • European Commission
  • Universidad Rey Juan Carlos
  • Instituto de Salud Carlos III
Topics
  • Health Sciences › Medicine › Epidemiology › Adipokines, Inflammation, and Metabolic Diseases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
  • Health Sciences › Medicine › Oncology › Cytokine Signaling Pathways and Interactions
Keywords
interleukin-6, insulin resistance, skeletal muscle, type 2 diabetes, PTP1B, JNK1/2, SOCS3, IRS-1 phosphorylation, GLUT4 translocation, liver X receptor agonist, glucose uptake, cytokines
MeSH terms
Adenylate Kinase, Animals, Animals, Newborn, Biological Transport, Extremities, Glucose, Insulin, Interleukin-6, Polymerase Chain Reaction, Muscle, Skeletal, Protein Transport, Muscle Cells, Myoblasts, RNA, Small Interfering, Proto-Oncogene Proteins c-akt, Glucose Transporter Type 4, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review